Erin S. Mackinnon

ON L5N0A4, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Erratum: Leiter et al. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Reviews in Cardiovascular Medicine. 2024; 25: 190.

Erratum: Leiter et al. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Reviews in Cardiovascular Medicine. 2024; 25: 190.

Journal: Reviews in cardiovascular medicine

Published: July 12, 2024

Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study.

Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study.

Journal: Cardiology and therapy

Published: November 20, 2023

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.

Journal: Cardiology and therapy

Published: August 02, 2023

Correction to: Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.

Correction to: Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.

Journal: Cardiology and therapy

Published: March 15, 2023

Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada.

Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada.

Journal: CJC open

Published: February 22, 2023

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.

Journal: Cardiology and therapy

Published: November 21, 2022

The Ubiquitin Proteasome System and Nutrient Stress Response.

The Ubiquitin Proteasome System and Nutrient Stress Response.

Journal: Frontiers in plant science

Published: February 01, 2022

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study.

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study.

Journal: CJC open

Published: January 25, 2022

Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.

Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.

Journal: CJC open

Published: August 03, 2021

Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study.

Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study.

Journal: Clinical cardiology

Published: June 23, 2021

Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice.

Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice.

Journal: International journal of women's health

Published: October 13, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026